RRPV Solicitation Summary: COVID-19 Monoclonal Antibody Therapeutics for PrEP
Inactive
Contract Opportunity
Notice ID
RPP-24-03-PrEP
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office
BARDA - ASPR / DAAPPO / BARDA DCMA
General Information
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Dec 01, 2023 03:47 pm EST
- Original Response Date: Jan 19, 2024 03:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Feb 03, 2024
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code: AN42 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
- NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Place of Performance:
Description
This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA), titled, “COVID-19 Monoclonal Antibody Therapeutics for PrEP".
The full RPP as well as information on joining the consortium can be accessed through the RRPV website at www.rrpv.org.
Attachments/Links
Contact Information
Contracting Office Address
- O’NEILL HOUSE OFFICE BUILDING
- WASHINGTON , DC 20515
- USA
Primary Point of Contact
- Rebecca Harmon
- rebecca.harmon@ati.org
Secondary Point of Contact
History
- Feb 03, 2024 11:55 pm ESTSpecial Notice (Original)